What first‑line FDA‑approved medication is recommended for an adult with alcohol use disorder who has no severe liver disease and no opioid use?

First-Line Medication for Alcohol Use Disorder

For an adult with alcohol use disorder who has no severe liver disease and no opioid use, either oral naltrexone 50 mg daily or acamprosate 666 mg three times daily should be prescribed as first-line pharmacotherapy, with both medications demonstrating comparable efficacy and FDA approval. 1, 2

Evidence-Based First-Line Options

Both naltrexone and acamprosate are FDA-approved medications with robust evidence supporting their use:

Naltrexone (Oral)

• Standard dosing: 50 mg once daily 1, 3
• Number needed to treat: 18 to prevent return to any drinking 1, 2
• Number needed to treat: 11 to prevent return to heavy drinking 2
• Reduces likelihood of return to any drinking by 5% and binge-drinking risk by 10% 4
• Must be initiated 3-7 days after last alcohol consumption, only after withdrawal symptoms have completely resolved 3
• Common side effects: nausea (risk ratio 1.73) and vomiting (risk ratio 1.53) compared to placebo 2

Acamprosate

• Standard dosing: 666 mg (two 333 mg tablets) three times daily for patients ≥60 kg 1, 5
• Number needed to treat: 11-12 to prevent return to any drinking 1, 2, 6
• Reduces relapse rates with odds ratio of 1.86 compared to placebo 5
• Must be initiated 3-7 days after last alcohol consumption, after withdrawal has resolved 5, 3
• Common side effect: diarrhea (risk ratio 1.58) 2
• No hepatic metabolism and no reported instances of hepatotoxicity 1, 5

Critical Timing Considerations

Both medications are for relapse prevention, NOT for acute withdrawal management:

• Benzodiazepines remain the gold standard for alcohol withdrawal syndrome 1, 3
• Long-acting benzodiazepines (diazepam, chlordiazepoxide) provide superior protection against seizures and delirium tremens 1
• Never initiate naltrexone or acamprosate during active withdrawal—this delays appropriate benzodiazepine therapy and provides no benefit for withdrawal symptoms 3

Choosing Between Naltrexone and Acamprosate

In patients without liver disease, either medication is appropriate as first-line therapy:

• A 2023 JAMA meta-analysis found both medications effective with similar numbers needed to treat 2
• The choice can be guided by patient preference regarding dosing frequency (once daily vs. three times daily) and side effect profile 2, 7
• Acamprosate may be preferred if there is any concern about liver function, as it has zero hepatotoxicity risk 1, 5, 6
• Naltrexone may be preferred for patients with renal impairment, as acamprosate requires dose adjustment with creatinine clearance 30-50 mL/min 5

Essential Combination with Psychosocial Treatment

Pharmacotherapy must be combined with psychosocial interventions for optimal outcomes:

• Cognitive behavioral therapy (CBT) combined with pharmacotherapy shows superior efficacy over usual care 1
• Motivational interviewing, motivational enhancement therapy, and 12-step facilitation are all evidence-based adjuncts 1
• Clinical benefit emerges over 3-12 months of consistent medication use alongside psychosocial interventions 5
• Treatment duration should be 3-6 months minimum, with extension up to 12 months 5, 8

Common Pitfalls to Avoid

• Do not prescribe disulfiram as first-line therapy—it is less effective than naltrexone or acamprosate and carries hepatotoxicity risk 1
• Do not start medication during active withdrawal—complete withdrawal management first 3
• Do not prescribe medication without concurrent psychosocial support—pharmacotherapy alone is insufficient 1, 3
• Do not expect immediate results—effectiveness is measured at minimum 12 weeks after treatment initiation 5

Alternative Considerations

If first-line medications fail or are not tolerated:

• Gabapentin (600-1,800 mg/day) has emerging evidence for efficacy 1, 7
• Topiramate (75-400 mg/day) shows promise in reducing heavy drinking 1, 7
• Injectable naltrexone (380 mg monthly) may improve adherence in selected patients 1, 2

1, 5, 3, 2, 6, 8, 4, 7